Syntacoll GmbH

Business Strategies

Development and Manufacturing of innovative collagen products for medical and pharmaceutical use.

Core Technologies

Development and production of sterile fibrillar atelo-collagen for haemostasis, surgical implantation with and without antibiotics, matrix for tissue engineering, carrier of biologically active substances, cytokines and growth factors and innovative formulations for new fields of application in matrix and carrier materials of medicine and biotechnology.

Tissue Engineering: Development of rapid and long-term equivalent for healing of acute and chronic wound and for immediate closing of superficial and deep wounds in burn patients. Further development of cartilage equivalent and/or implants for cartilage replacement and for healing superficial and deep cartilage defects using collagen matrix, cellular material and/or cartilage growth factors. As well as development of bone equivalent with and without addition of ceramics or cellular material and with collagen matrix and cell growth promoters inc. bone morphogenic proteins. Or connective tissue matrix for tendon and nerve regeneration.

Anti-inflammatory additives: Production and new developments of collagen/antibiotics and material suitable for implantation, new formulations of antibiotics release for a prolong drug delivery system.

Experimental test systems: Development of alternative collagen matrix based test system for pharmaceutical and cosmetic industry.

Patent, Licenses, Co-operations

Collagen based matrices for drug delivery, tissue substitution and wound healing for use i.e. in bones and connective tissue and the process of manufacturing such. Strategic cooperation with global operating US universities, medical centers and institutes. Development cooperation with German and US universities, medical centers and institutes.